stockrow
Friday 6 November 2026
Export CELC’s income statement to Excel — free account
Celcuity, Inc.
CELC Healthcare Biotechnology
- EPS
- −38.5%
- Free cash flow
- −53.3%
- Total debt
- +658.7%
Quarter to June 2026, against a year earlier
65.85
1.81
+2.83%
Follow CELC
Alert me
Celcuity, Inc. (CELC) Shares outstanding
Celcuity, Inc.'s shares outstanding at the end of fiscal 2025 was $46.8M, up 18.5% from $39.4M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $54.8M. Over the past ten years it has ranged from $5.8M (fiscal 2015) to $46.8M (fiscal 2025) — the current reading is the highest in ten years. Celcuity, Inc. ranks 276th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $46.8M | 18.53% |
| FY2024 | $39.4M | 66.60% |
| FY2023 | $23.7M | 53.57% |
| FY2022 | $15.4M | 15.21% |
| FY2021 | $13.4M | 30.35% |
| FY2020 | $10.3M | 0.40% |
| FY2019 | $10.2M | 1.00% |
| FY2018 | $10.1M | 35.71% |
| FY2017 | $7.5M | 18.18% |
| FY2016 | $6.3M | 8.04% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $54.8M | 0.65% |
| Mar 2026 | $54.5M | 16.48% |
| Dec 2025 | $46.8M | (1.75%) |
| Sep 2025 | $47.6M | 8.99% |
| 36 more quarters | Free account |
Against its own ten years
Low $5.8M
High $46.8M
Ten-year median
$10.3M
Current reading's percentile
100
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| DNLI Denali Therapeutics Inc. compare | $192.1M |
| DYN Dyne Therapeutics, Inc. compare | $165.5M |
| VKTX Viking Therapeutics, Inc. compare | $118.1M |
| VRDN Viridian Therapeutics, Inc. compare | $107.9M |
| IDYA IDEAYA Biosciences, Inc. compare | $102.9M |
| ELVN Enliven Therapeutics, Inc. compare | $66.2M |
| CELC Celcuity, Inc. | $54.8M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $46.4M |
| TLX Telix Pharmaceuticals Limited compare | — |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item